Advertisement

Spiroperidol Binding in the Human Caudate Nucleus

  • M. H. Winkler
  • S. Berl
  • W. O. WhetsellJr.
  • M. D. Yahr
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 16)

Summary

The displacement of spiroperidol binding by the optical isomers of butaclamol in synaptosomal preparations of the caudate nucleus obtained from parkinsonians and non-parkinsonians at post mortem were investigated. A group of spiroperidol binding sites found in the non-parkinsonians was less strongly expressed or absent in analogous tissue of the parkinsonian. The significance of these findings in relation to Parkinson’s disease and its treatment are discussed.

Keywords

Caudate Nucleus Optical Isomer High Affinity Site Mount Sinai School Synaptosomal Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Winkler, M.H., Nicklas, W.J., Berl, S.: J. Neurochem.32, 79–84 (1979).PubMedCrossRefGoogle Scholar
  2. [2]
    Greese , L , Burt, D.R.S., Snyder, S.H.: Life Sci. 17, 993–1002 (1975).Google Scholar
  3. [3]
    Schwarcz , R. , Kjell, F., Agnati, L. F., Gustafson , J.; Life Sci. 23, 465–470 (1978).CrossRefGoogle Scholar
  4. [4]
    Titeler , M. , Weinreich, P., Sinclair, D., Seeman, P.: Proc. Nat. Acad. Sci. 75, 1153–1156 (1978).PubMedGoogle Scholar
  5. [5]
    Beld , A.J , Kiujer, B., Rodriguez de Miranda, J. F., Wonterese, A. C.:Life Sci. 28 489 (1978).CrossRefGoogle Scholar
  6. [6]
    Hartley , E. J. , Seeman, P.: Life Sci. 23, 513–518 (1978).CrossRefGoogle Scholar
  7. [7]
    Leysen , J. E. , Gommeren, W., Laduron, P. M.: Biochem. Pharmac. 27, 307–316 (1978).CrossRefGoogle Scholar
  8. [8]
    Leysen , J. E. , Neimegeers, C. J. E., Tollenacre, J. P., Laduron, P. M.: Nature 272, 168–171 (1978).PubMedCrossRefGoogle Scholar
  9. [9]
    Leysen , J. E. , Gommeren, W.: Life Sci. 23, 447–452 (1978).PubMedGoogle Scholar
  10. [10]
    Jonsson , G. , Sachs, C.; European J. Pharmac. 16, 55 (1971).CrossRefGoogle Scholar
  11. [11]
    Symes , A.L. , Lal, S., Sourkes, T.L.: J. Pharm. Pharmacol. 29, 44–45 (1977).PubMedCrossRefGoogle Scholar
  12. [12]
    Puszkin , S. , Nicklas, W. J., Berl, S.: J. Neurochem. 19, 1319–1333 (1972).PubMedCrossRefGoogle Scholar
  13. [13]
    Hoss , W. , Reese, J.H., Smiley, C.: J. Neurosci. Res. 3, 257–266 (1977).PubMedGoogle Scholar
  14. [14]
    Reisine , T. D. , Fields, J. Z., Bird, E. D., Spokes, E., Yomomura, H. I.: Comm. Psychopharm. 2, 75–84 (1978).Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • M. H. Winkler
    • 1
  • S. Berl
    • 1
  • W. O. WhetsellJr.
    • 1
  • M. D. Yahr
    • 1
    • 2
  1. 1.The Clinical Center for Parkinson Research, Department of NeurologyThe Mount Sinai School of Medicine, City University of New YorkNew YorkUSA
  2. 2.Department of NeurologyThe Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations